Santa Monica, CANCT05685173Now EnrollingIRB Ready

B-cell Non-Hodgkins Lymphoma (B-NHL) Clinical Trial in Santa Monica, CA

Access cutting-edge b-cell non-hodgkins lymphoma (b-nhl) treatment through this clinical trial at a research site in Santa Monica. Study-provided care at no cost to qualified participants.

Sponsored by Regeneron Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Santa Monica location

Preparing your pre-screening questions…

Expert Care in Santa Monica

Access b-cell non-hodgkins lymphoma (b-nhl) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related b-cell non-hodgkins lymphoma (b-nhl) treatment provided free

Apply for This Santa Monica Location

Check if you qualify for this b-cell non-hodgkins lymphoma (b-nhl) clinical trial in Santa Monica, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Santa Monica

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Santa Monica site if eligible
  4. 4Begin participation

About This B-cell Non-Hodgkins Lymphoma (B-NHL) Study in Santa Monica

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (dose escalation) is to find a safe dose of REGN5837 when given in combination with odronextamab. The goal of the second part (dose expansion) is to use the REGN5837 drug dose found in the first part to see how well REGN5837 in combination with odronextamab works. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)

Sponsor: Regeneron Pharmaceuticals

Who Can Participate

Inclusion Criteria

Have documented CD20+ aggressive B-NHL, with disease that has progressed after at least 2 lines of systemic therapy containing an anti-CD20 antibody and an alkylating agent, as described in the protocol.
Measurable disease on cross sectional imaging as defined in the protocol
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Adequate bone marrow, renal and hepatic function as defined in the protocol
Availability of tumor tissue for submission to central laboratory is required for study enrollment. Archival tumor tissue for histological assessment prior to enrollment is allowed
During dose expansion phase of the study, participant should be willing to undergo mandatory tumor biopsies, if in the opinion of the investigator, the participant has an accessible lesion that can be biopsied without significant risk to the participant. Key

Exclusion Criteria

Prior treatments with allogeneic stem cell transplantation or solid organ transplantation, treatment with anti-CD20 x anti- CD3 bispecific antibody, such as odronextamab
Diagnosis of Mantle Cell Lymphoma (MCL)
Primary Central Nervous System (CNS) lymphoma or known involvement by non-primary CNS lymphoma, as described in the protocol
Treatment with any systemic anti-lymphoma therapy within 5 half-lives or within 14 days prior to first administration of study drug, whichever is shorter, as described in the protocol
Standard radiotherapy within 14 days of first administration of study drug, as described in the protocol
Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or corticosteroid equivalent within 72 hours of start of odronextamab
Co-morbid conditions, as described in the protocol
Infections, as described in the protocol
Allergy/hypersensitivity: Known hypersensitivity to both allopurinol and rasburicase NOTE: Other protocol defined inclusion / exclusion criteria apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Santa Monica?

Yes, this clinical trial (NCT05685173) has an active research site in Santa Monica, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

B-cell Non-Hodgkins Lymphoma (B-NHL) Treatment Options in Santa Monica, CA

If you're searching for b-cell non-hodgkins lymphoma (b-nhl) treatment options in Santa Monica, CA, this clinical trial (NCT05685173) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Santa Monica research site is actively enrolling participants for this clinical trial. You'll receive care from experienced b-cell non-hodgkins lymphoma (b-nhl) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all b-cell non-hodgkins lymphoma (b-nhl) clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Santa Monica, CA

See all lymphoma clinical trials recruiting in Santa Monica — not just this study.

Browse Lymphoma Trials in Santa Monica

Ready to Join in Santa Monica?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Santa Monica, CA